{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058017","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.955297+00:00","generated_at":"2026-06-02T15:33:27.372466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO","bullets":["TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.","REZLIDHIA net sales $4.9M, up from $1.5M YoY, driven by increased demand.","Net loss improved to $8.2M ($0.05/sh) from $13.5M ($0.08/sh) in Q1 2023.","Acquired U.S. rights to GAVRETO (pralsetinib) for RET fusion-positive NSCLC/thyroid cancer; transition expected July 2024.","Cash and short-term investments $49.6M at March 31, 2024; credit facility amendment extended maturity by one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058017","json":"https://secwatch.observer/filing/0001104659-24-058017.json","markdown":"https://secwatch.observer/filing/0001104659-24-058017.md","text":"https://secwatch.observer/filing/0001104659-24-058017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/0001104659-24-058017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/tm2413689d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:33:27.372466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"320167a6c15bdb4d58d4f134e6d86aaf2bffd7b3","claim":"RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2024 results: revenue $29.5 million.","evidence_excerpt":"2 tm2413689d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO ® , a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/0001104659-24-058017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$29.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}